Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...

An update from SinoMab Bioscience Ltd. ( ($HK:3681) ) is now available. SinoMab BioScience Limited announced that its Investigational New Drug ...

An increasing number of people are suffering from gastrointestinal disorders (GIDs) due to unhealthy diet habits and the stress of the fast pace of modern life. Most of these people will be ...

Discover how in silico tools can be used can be used with organ-on-a-chip for the advancement of ADME studies.

Pancreatic cancer is one of the deadliest malignancies, with survival rates remaining dismally low despite major advances in ...

Streamlined pharmacologic recommendations challenge the stepwise approach for moderately to severely active disease.

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...

Gram-negative bacteria, notorious for their intrinsic and acquired resistance mechanisms, pose a significant threat to public health. The emergence of ...

The FDA has approved Linzess (linaclotide) for treatment of irritable bowel syndrome with constipation (IBS-C) in patients 7 years of age and older.

The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.